Regulation of the IL-33 receptor, ST2L, by Protein Stability in Septic Injury

脓毒性损伤中蛋白质稳定性对 IL-33 受体 ST2L 的调节

基本信息

  • 批准号:
    8499556
  • 负责人:
  • 金额:
    $ 35.8万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2013
  • 资助国家:
    美国
  • 起止时间:
    2013-06-01 至 2017-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): IL-33, acting via its receptor, ST2L, is a highly potent cytokine implicated in septic injury. The IL-33/ST2L axis appears indispensable in inflammatory signaling as blockade of the ST2L receptor significantly attenuates systemic inflammation. Thus, maneuvers designed to selectively modulate availability of ST2L might lessen the severity of sepsis. However, to date, very little is known regarding the molecular regulation of ST2L expression. In the process of studying bacterial sepsis, we discovered that a new orphan protein, FBXL19 (F-box protein 19, SCFFBXL19), specifically targets phosphorylated ST2L for its ubiquitination and degradation. Our published and preliminary works also shows that ST2L is phosphorylated by glycogen synthase kinase (GSK3¿), and that activation of the IL-33/ST2L axis induces cleavage of PARP and PKC¿ thereby promoting apoptosis. Further, FBXL19 mediated disposal of ST2L attenuates IL-33/ST2L-induced pro-inflammatory signaling, apoptosis, and lessens the severity of inflammatory organ injury in septic murine models. These data led to our novel hypothesis that GSK3¿-driven phosphorylation of ST2L serves as a molecular signature for F-box protein mediated ubiquitination and degradation of ST2L in sepsis-associated injury. We will test this hypothesis by executing two specific Aims: (1) To investigate the mechanisms by which GSK3¿ promotes ST2L degradation and regulates IL-33/ST2L signaling, and (2) To investigate the mechanisms by which FBXL19 and its ligand promotes ST2L ubiquitination and degradation thereby attenuating septic lung injury. These studies will lay the groundwork for a significant mechanistic advance with regard to the molecular regulation of a relatively new receptor (ST2L) involved in sepsis. Results from these studies are intended to serve as the basis for strategies directed at the development of novel small molecule inhibitors of the IL-33/ST2L pathway to lessen the severity of sepsis-induced organ injury.
描述(由申请人提供):IL-33通过其受体ST2L起作用,是一种与脓毒性损伤有关的高效细胞因子。IL-33/ST2L轴在炎症信号传导中是不可或缺的,因为ST2L受体的阻断可显著减轻全身性炎症。因此,选择性调节ST2L可用性的策略可能会减轻败血症的严重程度。然而,迄今为止,关于ST2L表达的分子调控知之甚少。在研究细菌性脓毒症的过程中,我们发现一种新的孤儿蛋白FBXL19 (F-box protein 19, SCFFBXL19)特异性靶向磷酸化的ST2L泛素化和降解。我们发表的和初步的研究也表明,ST2L被糖原合成酶激酶(GSK3¿)磷酸化,并且IL-33/ST2L轴的激活诱导PARP和PKC¿的切割,从而促进细胞凋亡。此外,FBXL19介导的ST2L处理可以减弱IL-33/ST2L诱导的促炎信号和细胞凋亡,并减轻脓毒症小鼠模型中炎症器官损伤的严重程度。这些数据导致了我们的新假设,即GSK3驱动的ST2L磷酸化是F-box蛋白介导的泛素化和ST2L降解在败血症相关损伤中的分子特征。我们将通过两个具体目的来验证这一假设:(1)研究GSK3¿促进ST2L降解和调节IL-33/ST2L信号传导的机制;(2)研究FBXL19及其配体促进ST2L泛素化和降解从而减轻脓毒性肺损伤的机制。这些研究将为一种相对较新的受体(ST2L)参与脓毒症的分子调控的重大机制进展奠定基础。这些研究的结果旨在为开发IL-33/ST2L通路的新型小分子抑制剂以减轻脓毒症诱导的器官损伤的严重程度提供策略基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yutong Zhao其他文献

Yutong Zhao的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yutong Zhao', 18)}}的其他基金

Molecular regulation of BMPRII stability in lung fibrosis
肺纤维化中 BMPRII 稳定性的分子调节
  • 批准号:
    10712273
  • 财政年份:
    2023
  • 资助金额:
    $ 35.8万
  • 项目类别:
ISGylation regulates lung endothelial inflammation
ISGylation 调节肺内皮炎症
  • 批准号:
    10180376
  • 财政年份:
    2021
  • 资助金额:
    $ 35.8万
  • 项目类别:
ISGylation regulates lung endothelial inflammation
ISGylation 调节肺内皮炎症
  • 批准号:
    10394303
  • 财政年份:
    2021
  • 资助金额:
    $ 35.8万
  • 项目类别:
ISGylation regulates lung endothelial inflammation
ISGylation 调节肺内皮炎症
  • 批准号:
    10614448
  • 财政年份:
    2021
  • 资助金额:
    $ 35.8万
  • 项目类别:
Molecular regulation of anti-inflammatory cytokine receptor in sepsis
脓毒症抗炎细胞因子受体的分子调控
  • 批准号:
    9912821
  • 财政年份:
    2018
  • 资助金额:
    $ 35.8万
  • 项目类别:
Regulation of proteolysis by deubiquiting enzyme in lung inflammatory disease
肺部炎症疾病中去泛素化酶对蛋白水解的调节
  • 批准号:
    9912813
  • 财政年份:
    2018
  • 资助金额:
    $ 35.8万
  • 项目类别:
Regulation of proteolysis by deubiquiting enzyme in lung inflammatory disease
肺部炎症疾病中去泛素化酶对蛋白水解的调节
  • 批准号:
    9237362
  • 财政年份:
    2017
  • 资助金额:
    $ 35.8万
  • 项目类别:
Regulation of the IL-33 receptor, ST2L, by Protein Stability in Septic Injury
脓毒性损伤中蛋白质稳定性对 IL-33 受体 ST2L 的调节
  • 批准号:
    8851660
  • 财政年份:
    2013
  • 资助金额:
    $ 35.8万
  • 项目类别:
Regulation of the IL-33 receptor, ST2L, by Protein Stability in Septic Injury
脓毒性损伤中蛋白质稳定性对 IL-33 受体 ST2L 的调节
  • 批准号:
    8666032
  • 财政年份:
    2013
  • 资助金额:
    $ 35.8万
  • 项目类别:
Regulation of the IL-33 receptor, ST2L, by Protein Stability in Septic Injury
脓毒性损伤中蛋白质稳定性对 IL-33 受体 ST2L 的调节
  • 批准号:
    9067468
  • 财政年份:
    2013
  • 资助金额:
    $ 35.8万
  • 项目类别:

相似海外基金

Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
  • 批准号:
    10648387
  • 财政年份:
    2023
  • 资助金额:
    $ 35.8万
  • 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
  • 批准号:
    10591804
  • 财政年份:
    2023
  • 资助金额:
    $ 35.8万
  • 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
  • 批准号:
    10741574
  • 财政年份:
    2023
  • 资助金额:
    $ 35.8万
  • 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
  • 批准号:
    10720687
  • 财政年份:
    2023
  • 资助金额:
    $ 35.8万
  • 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
  • 批准号:
    10719249
  • 财政年份:
    2023
  • 资助金额:
    $ 35.8万
  • 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
  • 批准号:
    23K07651
  • 财政年份:
    2023
  • 资助金额:
    $ 35.8万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
  • 批准号:
    10679944
  • 财政年份:
    2023
  • 资助金额:
    $ 35.8万
  • 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
  • 批准号:
    10575258
  • 财政年份:
    2023
  • 资助金额:
    $ 35.8万
  • 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
  • 批准号:
    10701207
  • 财政年份:
    2023
  • 资助金额:
    $ 35.8万
  • 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
  • 批准号:
    10837431
  • 财政年份:
    2023
  • 资助金额:
    $ 35.8万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了